- Latest available (Revised)
- Original (As adopted by EU)
When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.
Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).
This is the original version as it was originally adopted in the EU.
This legislation may since have been updated - see the latest available (revised) version
THE EUROPEAN COMMISSION,
Having regard to the Treaty on European Union and to the Treaty on the Functioning of the European Union,
Having regard to Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use(1), and in particular Article 16(f) thereof,
Having regard to the opinions of the European Medicines Agency, formulated on 10 January 2008 and 6 March 2008 by the Committee for Herbal Medicinal Products,
Whereas:
(1) ‘Eleutherococcus senticosus (Rupr. et Maxim.) Maxim’ and ‘Echinacea purpurea (L.) Moench’ comply with the requirements set out in Directive 2001/83/EC. ‘Eleutherococcus senticosus (Rupr. et Maxim.) Maxim’ and ‘Echinacea purpurea (L.) Moench’ can be considered as herbal substances, herbal preparations or combinations thereof.
(2) It is therefore appropriate to include ‘Eleutherococcus senticosus (Rupr. et Maxim.) Maxim’ and ‘Echinacea purpurea (L.) Moench’ in the list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products established in Annex I to Commission Decision 2008/911/EC(2).
(3) Decision 2008/911/EC should therefore be amended accordingly.
(4) The measures provided for in this Decision are in accordance with the opinion of the Standing Committee on Medicinal Products for Human Use,
HAS ADOPTED THIS DECISION:
Decision 2008/911/EC is amended as follows:
Annex I is amended in accordance with Annex I to this Decision;
Annex II is amended in accordance with Annex II to this Decision.
This Decision is addressed to the Member States.
Done at Brussels, 9 December 2009.
For the Commission
Günter Verheugen
Vice-President
In Annex I to Decision 2008/911/EC, the following two substances are inserted after ‘Calendula officinalis L.’:
‘Echinacea purpurea (L.) Moench’
‘Eleutherococcus senticosus (Rupr. et Maxim.) Maxim’
In Annex II to Decision 2008/911/EC, the following is inserted after the entry relating to ‘Calendula officinalis L’:
Echinacea purpurea (L.) Moench
Asteraceae
Purple coneflower herb
BG (bălgarski): пурпурна ехинацея, пресен стрък
CS (čeština): čerstvá nať třapatky nachové
DA (dansk): Purpursolhat, frisk urt
DE (Deutsch): Purpursonnenhutkraut, frisch
EL (elliniká): Πόα Εχινάκεας της πορφυράς
EN (English): purple coneflower herb
ES (español): Equinácea purpúrea, partes aéreas incluidas sumidades floridas
ET (eesti keel): punane siilkübar
FI (suomi): kaunopunahattu, tuore verso
FR (français): parties aériennes fraîches d’échinacée pourpre
HU (magyar): bíbor kasvirág virágos hajtása
IT (italiano): Echinacea purpurea, pianta fresca
LT (lietuvių kalba): rausvažiedžių ežiuolių žolė
LV (latviešu valoda): purpursarkanās ehinacejas laksti
MT (malti): Echinacea Vjola
NL (nederlands): rood zonnehoedkruid
PL (polski): jeżówka purpurowa, świeże ziele
PT (português): Equinácea, partes aéreas floridas
RO (română): iarbã proaspãtã de Echinacea, pãlãria soarelui
SK (slovenčina): echinacea purpurová, čerstvá vňať
SL (slovenščina): sveža zel škrlatne ehinaceje
SV (svenska): röd solhatt, färsk ört
IS (íslenska): Sólhattur
NO (norsk): Rød solhatt
Expressed juice and dried expressed juice from fresh flowering aerial parts.
N/A
Traditional herbal medicinal product for treatment of small superficial wounds.
The product is a traditional herbal medicinal product for use in a specified indication exclusively based on long-standing use.
European.
10 to 20 g/100 g of expressed juice or equivalent amount of dried expressed juice in liquid or semi-solid dosage forms.
Adolescents over the age of 12 years, adults, elderly
Small amount of ointment is applied on the affected area 2-3 times a day.
The use in children under 12 years of age is not recommended (see below “Special warnings and precautions for use”).
Cutaneous use.
Do not use the medicinal product for more than 1 week.
If the symptoms persist during the use of the medicinal product, a doctor or a qualified healthcare practitioner should be consulted.
Hypersensitivity to the active substance or to plants of the Asteraceae (Compositae) family.
If signs of skin infection are observed, medical advice should be sought.
The use in children below 12 years of age is not recommended because a safe use has not been sufficiently documented.
None reported.
There are no data on cutaneous use during pregnancy or lactation.
Products containing Echinacea should not be applied to the breast of breastfeeding women.
No studies on the effects on the ability to drive and use machines have been performed.
Hypersensitive reactions (local rash, contact dermatitis, eczema and angioedema of the lips) may occur.
The frequency is not known.
If other adverse reactions not mentioned above occur, a doctor or a qualified healthcare practitioner should be consulted.
No case of overdose has been reported.
Eleutherococcus senticosus (Rupr. et Maxim.) Maxim.
Araliaceae
Eleutherococcus root
BG (bălgarski): елеутерокок, корен
CS (čeština): eleuterokokový kořen
DA (dansk): Russisk rod
DE (Deutsch): Taigawurzel
EL (elliniká): Pίζα Eλευθεροκόκκου
EN (English): Eleutherococcus root
ES (español): Eleuterococo, raíz de
ET (eesti keel): eleuterokokijuur
FI (suomi): venäjänjuuren juuri
FR (français): racine d’éleuthérocoque (racine de ginseng sibérien)
HU (magyar): Szibériai ginszeng gyökér (tajga gyökér)
IT (italiano): Eleuterococco radice
LT (lietuvių kalba): Eleuterokokų šaknys
LV (latviešu valoda): Eleiterokoka sakne
MT (malti): Għerq ta’ l-elewterokokku
NL (nederlands): Russische ginsengwortel
PL (polski): korzeń eleuterokoka
PT (português): Raiz de Ginseng Siberiano
RO (română): Rădăcină de ginseng siberian
SK (slovenčina): Všehojovcový koreň
SL (slovenščina): korenina elevterokoka
SV (svenska): Rysk rot
IS (íslenska): Síberíu ginseng, rót
NO (norsk): Russisk rot
Comminuted herbal substance for preparation of a herbal tea
Liquid extract (1:1, ethanol 30-40 % v/v)
Dry extract (13-25: 1, ethanol 28-40 % v/v)
Dry extract (17-30: 1, ethanol 70 % v/v)
Dry aqueous extract (15-17:1)
Tincture (1:5, ethanol 40 % v/v)
Eleutherococcus — Eleutherococci radix (ref.: 01/2008: 1419 corrected 6.0)
Traditional herbal medicinal product for symptoms of asthenia such as fatigue and weakness.
The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use.
Chinese, European.
Not applicable.
Adolescents over 12 years of age, adults, elderly
Herbal preparations.
Daily dose.
Comminuted herbal substance as herbal tea: 0,5-4 g.
Tea preparation: 0,5 to 4 g of comminuted herbal substance for infusion in 150 ml of boiling water.
Dosage frequency: 150 ml of tea infusion should be divided in one to three doses taken during the day.
Liquid extract: 2-3 ml.
Dry extracts (ethanol 28-70 % v/v) corresponding to 0,5-4 g dried root.
Dry aqueous extract (15-17:1): 90-180 mg.
Tincture: 10-15 ml.
The daily dose can be taken in one to three doses.
The use is not recommended in children under 12 years of age (see below “Special warnings and precautions for use”).
Oral use.
Not to be taken for more than 2 months.
If the symptoms persist for more than 2 weeks during the use of the medicinal product, a doctor or a qualified healthcare practitioner should be consulted.
Hypersensitivity to the active substance.
Arterial hypertension.
The use in children under 12 years of age is not recommended because sufficient experience is not available.
If the symptoms worsen during the use of the medicinal product, a doctor or a qualified healthcare practitioner should be consulted.
None reported.
Safety during pregnancy and lactation has not been established.
In the absence of sufficient data, the use during pregnancy and lactation is not recommended.
No studies on the effect on the ability to drive and use machines have been performed.
Insomnia, irritability, tachycardia and headaches may occur. The frequency is not known.
No case of overdose has been reported.’
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including:
The data on this page is available in the alternative data formats listed: